Division of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045, Japan.
Department of Gastric Surgery, National Cancer Center Hospital, Tokyo, Japan.
J Gastroenterol. 2021 Nov;56(11):988-998. doi: 10.1007/s00535-021-01823-x. Epub 2021 Sep 12.
Recent studies highlighted the clinicopathological heterogeneity of non-ampullary duodenal adenomas and adenocarcinomas, but the detailed process of the malignant transformation remains unclear.
We analyzed 144 adenomas and 54 adenocarcinomas of the non-ampullary duodenum for immunohistochemical phenotypes, genetic alterations, and mismatch repair (MMR) status to probe their histogenetic relationship.
The median ages of patients with adenoma and adenocarcinoma were the same (66 years). Adenomas were histologically classified as intestinal-type adenoma (n = 124), pyloric gland adenoma (PGA, n = 10), gastric-type adenoma, not otherwise specified (n = 9), and foveolar-type adenoma (n = 1). Protein-truncating APC mutations were highly frequent in adenomas (85%), with the highest prevalence in intestinal-type adenomas (89%), but rare in adenocarcinomas (9%; P = 2.1 × 10). Close associations between phenotypic marker expression and genetic alterations were observed in adenomas, but not in adenocarcinomas, excluding the common association between GNAS mutations and MUC5AC expression. MMR deficiency was more frequent in adenocarcinomas (20%) than in adenomas (1%; P = 2.6 × 10). One MMR-deficient adenoma and three MMR-deficient adenocarcinomas occurred in patients with Lynch syndrome. Additionally, three other patients with an MMR-deficient adenocarcinoma fulfilled the revised Bethesda criteria.
The discrepant APC mutation frequency between adenomas and adenocarcinomas suggests that APC-mutated adenomas, which constitute the large majority of non-ampullary duodenal adenomas, are less prone to malignant transformation. Non-ampullary duodenal adenocarcinomas frequently exhibit MMR deficiency and should be subject to MMR testing to determine appropriate clinical management, including the identification of patients with Lynch syndrome.
最近的研究强调了非壶腹十二指肠腺瘤和腺癌的临床病理异质性,但恶性转化的详细过程仍不清楚。
我们分析了 144 例非壶腹十二指肠腺瘤和 54 例腺癌,以探讨其组织发生关系,包括免疫组织化学表型、遗传改变和错配修复(MMR)状态。
腺瘤和腺癌患者的中位年龄相同(66 岁)。腺瘤的组织学分类为肠型腺瘤(n=124)、幽门腺腺瘤(PGA,n=10)、胃型腺瘤、未另作说明(n=9)和滤泡型腺瘤(n=1)。腺瘤中蛋白截断 APC 突变高度频繁(85%),肠型腺瘤中最高(89%),但腺癌中罕见(9%;P=2.1×10)。在腺瘤中观察到表型标志物表达与遗传改变之间的密切关联,但在腺癌中没有,排除了 GNAS 突变和 MUC5AC 表达之间的常见关联。MMR 缺陷在腺癌(20%)中比腺瘤(1%)中更为常见(P=2.6×10)。在 Lynch 综合征患者中,有一个 MMR 缺陷腺瘤和三个 MMR 缺陷腺癌。此外,其他三个 MMR 缺陷腺癌患者符合修订后的 Bethesda 标准。
腺瘤和腺癌之间 APC 突变频率的差异表明,构成非壶腹十二指肠腺瘤绝大多数的 APC 突变腺瘤恶性转化的可能性较小。非壶腹十二指肠腺癌常表现为 MMR 缺陷,应进行 MMR 检测,以确定适当的临床管理,包括识别 Lynch 综合征患者。